The record

LegislationLegislation· Jul 2026
HR 5160 Passed House — in Senate

Sponsored by Christopher H. Smith (R)

Stem Cell Therapeutic and Research Reauthorization Act of 2025

Reauthorizes federal programs funding bone marrow and cord blood transplants through 2031.

Tradeoff

Extends funding for cell transplant programs serving patients needing donor bone marrow or cord blood. No offsetting cuts or revenue changes cited.

What's in it

See official bill text

Requires $233 million in over 2026–2031, with an additional $42 million after 2031, assuming Congress the authorized amounts.

The $233 million funds bone marrow transplant support, umbilical cord blood collection and storage, and stem cell research through federal programs over six years, with annual of $33 million for transplantation and $23 million for cord blood inventory.

H.R. 5160, Stem Cell Therapeutic and Research Reauthorization Act of 2025 · Aug 2026

Passed the House by on July 20, 2026 — sitting in the Senate.

  1. House

    Introduced

    (Sep 4, 2025)

  2. House

    Committee on Energy and Commerce(Sep 4, 2025)

  3. House

    The Committee on Energy and Commerce voted to send it to the floor

    Reported 48 - 0(May 21, 2026)

    Committee report H. Rept. 119-724.

  4. House

    Passage of the bill

    Passed by (Jul 20, 2026)

    No individual votes were recorded.

  5. Senate

    Received from the House

    Received(Jul 21, 2026)